Societe de Therapeutique Marocaine S.A., a pharmaceutical company, manufactures and sells medicines in Morocco.
Price History & Performance
|Historical stock prices|
|Current Share Price||د.م1,497.00|
|52 Week High||د.م418.75|
|52 Week Low||د.م1,750.00|
|1 Month Change||-0.86%|
|3 Month Change||21.71%|
|1 Year Change||n/a|
|3 Year Change||276.84%|
|5 Year Change||380.96%|
|Change since IPO||1,022.76%|
Recent News & Updates
|SOT||MA Pharmaceuticals||MA Market|
Return vs Industry: Insufficient data to determine how SOT performed against the MA Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SOT performed against the MA Market.
Stable Share Price: SOT is more volatile than 90% of MA stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: SOT's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of MA stocks.
About the Company
Societe de Therapeutique Marocaine S.A., a pharmaceutical company, manufactures and sells medicines in Morocco. It offers antibiotics; and allergology, oncology, cardiology, dental, dermatology, endocrinology, gastroenterology, gynecology, ophthalmology, ENT, pediatric, pulmonology, reanimation, rheumatology, CNS, and urology, as well as other generic drugs. The company offers its products in various forms, such as tablets, capsules, pouches, syrups, suspensions, powders, collyriums, suppositories, creams and pomades, injectable solutions, and self-injectable syringes.
Societe de Therapeutique Marocaine Fundamentals Summary
|SOT fundamental statistics|
Is SOT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SOT income statement (TTM)|
|Cost of Revenue||د.م1.00b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||34.61|
|Net Profit Margin||12.85%|
How did SOT perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is Societe de Therapeutique Marocaine undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SOT (MAD1497) is trading above our estimate of fair value (MAD257.73)
Significantly Below Fair Value: SOT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SOT is poor value based on its PE Ratio (43.3x) compared to the African Pharmaceuticals industry average (9.4x).
PE vs Market: SOT is poor value based on its PE Ratio (43.3x) compared to the MA market (26.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SOT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SOT is overvalued based on its PB Ratio (9.3x) compared to the XF Pharmaceuticals industry average (1.5x).
How is Societe de Therapeutique Marocaine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Societe de Therapeutique Marocaine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Societe de Therapeutique Marocaine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SOT has high quality earnings.
Growing Profit Margin: SOT's current net profit margins (12.8%) are lower than last year (14%).
Past Earnings Growth Analysis
Earnings Trend: SOT's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: SOT's earnings growth over the past year (5.9%) is below its 5-year average (12.5% per year).
Earnings vs Industry: SOT earnings growth over the past year (5.9%) underperformed the Pharmaceuticals industry 10%.
Return on Equity
High ROE: SOT's Return on Equity (21.7%) is considered high.
How is Societe de Therapeutique Marocaine's financial position?
Financial Position Analysis
Short Term Liabilities: SOT's short term assets (MAD1.3B) exceed its short term liabilities (MAD743.0M).
Long Term Liabilities: SOT's short term assets (MAD1.3B) exceed its long term liabilities (MAD216.4M).
Debt to Equity History and Analysis
Debt Level: SOT's debt to equity ratio (22.9%) is considered satisfactory.
Reducing Debt: SOT's debt to equity ratio has reduced from 27% to 22.9% over the past 5 years.
Debt Coverage: SOT's debt is well covered by operating cash flow (71.8%).
Interest Coverage: SOT's interest payments on its debt are well covered by EBIT (42.6x coverage).
What is Societe de Therapeutique Marocaine current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SOT's dividend (0.35%) isn’t notable compared to the bottom 25% of dividend payers in the MA market (2.22%).
High Dividend: SOT's dividend (0.35%) is low compared to the top 25% of dividend payers in the MA market (4.86%).
Stability and Growth of Payments
Stable Dividend: SOT is not paying a notable dividend for the MA market, therefore no need to check if payments are stable.
Growing Dividend: SOT is not paying a notable dividend for the MA market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: SOT is not paying a notable dividend for the MA market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SOT's dividend in 3 years as they are not forecast to pay a notable one for the MA market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Ms. Lamia Tazi serves as Chairman and Chief Executive Officer at Societe de Therapeutique Marocaine S.A. and its Director since May 17, 2001. Ms. Tazi served as the Managing Director of Pharmacy at Societe...
Experienced Board: SOT's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Societe de Therapeutique Marocaine S.A.'s employee growth, exchange listings and data sources
- Name: Societe de Therapeutique Marocaine S.A.
- Ticker: SOT
- Exchange: CBSE
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: د.م10.778b
- Shares outstanding: 7.20m
- Website: https://www.sothema.com
Number of Employees
- Societe de Therapeutique Marocaine S.A.
- Z.I. Bouskoura
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 16:30|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.